Selected Start-Ups (10/00)
Executive Summary
In Vivo summarizes the technologies of several recently founded companies: Spun out of London's Imperial College School of Medicine in July, Circassia Ltd. will develop treatments for cat-induced asthma and allergies. Copharos Inc., was formed in August 2000 to develop Vitamin B12-based radioactive imaging and therapeutic agents for the early detection and treatment of breast, lung and other cancers. EyeTech Pharmaceuticals Inc., founded in April 2000, has embarked on Phase IB trials for its drug for wet macular degeneration, a leading cause of adult-onset blindness. Invenux Inc. will use its Evolutionary Chemistry integrated discovery system to identify antibiotic compounds effective against drug-resistant organisms as well as discover drugs with broad-spectrum antibiotic activity. Sensatex/Lifelink Inc. will provide wireless, remote health care monitoring with its Smart Shirt, a special fabric interwoven with sensors that continuously relays information on a patient's vital signs. Sensory Technologies Inc. was formed in November 1999 to commercialize sensory-enhancement research of James Collins, PhD at Boston University's Center for Biodynamics.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.